Form 4: ARTL Director Emanuele Granted Stock Options

ARTELO BIOSCIENCES, INC. Director Robert Martin Emanuele was granted 292 stock options with an exercise price of $1.71, vesting on January 30, 2026.

Summary

• Robert Martin Emanuele, a Director of ARTELO BIOSCIENCES, INC. (ARTL), was granted 292 stock options.
• The options have an exercise price of $1.71 per share.
• The transaction date for the grant was January 30, 2026, which is also designated as the Vesting Commencement Date.
• The options are scheduled to expire on January 30, 2036.
• One hundred percent (100%) of the shares subject to the option will vest on the earlier of (i) the one-year anniversary of the Vesting Commencement Date (January 30, 2026), or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date.
• Following this transaction, Mr. Emanuele beneficially owns 292 derivative securities directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine compensation event for a director, indicating continued alignment of interests with shareholders through equity grants, which is generally a neutral to slightly positive signal.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term performance.
• The options were granted at an exercise price of $1.71, indicating a specific valuation at the time of grant.

Future Outlook

The filing indicates that 100% of the granted stock options will vest on the earlier of the one-year anniversary of the Vesting Commencement Date (January 30, 2026) or the day prior to the next annual meeting of stockholders following that date.

Industry Context

StockSavvy.ai notes that the grant of stock options to directors is a common practice in the biotechnology industry and across public companies, serving as a form of equity compensation to attract, retain, and incentivize leadership by aligning their interests with long-term shareholder value.

Related Party Transactions

• The grant of stock options to Robert Martin Emanuele, a Director, constitutes a related party transaction as part of his compensation.

Stakeholder Impact

• Shareholders: Potential for minor dilution if options are exercised in the future, but also increased alignment of director's interests with shareholder value creation.

Next Steps

• The stock options will vest on the earlier of January 30, 2027, or the day prior to the next annual meeting of stockholders following January 30, 2026.

Key Dates

Recommendation

This Form 4 reports a routine equity grant to a director as part of their compensation. While it aligns the director's interests with shareholders, it does not provide new fundamental information about the company's operational or financial performance to warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate based solely on this filing.

Keywords

ARTELO BIOSCIENCES, ARTL, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Biotechnology